

Eupafolin ameliorates lipopolysaccharide-induced cardiomyocyte autophagy via PI3K/AKT/mTOR signaling pathway

Yan Gao ^{1*}, Yi Zhang ², Yangyang Fan ³

¹ Function Testing Lab, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi P.R. China

² ICU Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi P.R. China

³ Obstetrical Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi P.R. China

ARTICLE INFO

Article type:

Original article

Article history:

Received: Jan 17, 2019

Accepted: Jul 3, 2019

Keywords:

Autophagy
Cardiomyocyte
Eupafolin
Lipopolysaccharides
Mammalian target of rapamycin

ABSTRACT

Objective(s): Eupafolin, a major active component of *Eupatorium perfoliatum L.*, has anti-inflammatory and anti-oxidant properties. Lipopolysaccharide (LPS) is responsible for myocardial depression. A line of evidences revealed that LPS induces autophagy in cardiomyocytes injury. This study aims to evaluate the effects of eupafolin on LPS-induced cardiomyocyte autophagy.

Materials and Methods: The effect of LPS on cell viability was examined by CCK-8. Autophagic protein 2 light chain 3 (LC3II), which was regulated by LPS and eupafolin, was examined using immunofluorescent staining. The expression levels of Beclin-1 and p62 were detected by western blotting. The effects of eupafolin on phosphatidylinositol-3-kinase/ protein kinase B/ mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway were also evaluated by western blotting and immunofluorescent staining.

Results: Eupafolin pretreatment reduced the expression of LC3II and Beclin-1, whereas p62 was significant increased. In addition, eupafolin promoted expression of PI3K/AKT/mTOR signaling pathway and mTOR inhibitor rapamycin reversed the inhibitory effects on LPS-induced cardiomyocyte autophagy.

Conclusion: Eupafolin exerts anti-autophagy activity via activation of PI3K/AKT/mTOR signaling pathway.

► Please cite this article as:

Gao Y, Zhang Y, Fan Y. Eupafolin ameliorates lipopolysaccharide-induced cardiomyocyte autophagy via PI3K/AKT/mTOR signaling pathway. Iran J Basic Med Sci 2019; 22:1340-1346. doi: 10.22038/ijbms.2019.37748.8977

Introduction

A variety of heart diseases including cardiac hypertrophy and ischemia reperfusion injury were observed with autophagy activation (1). Autophagy is an intracellular degradation process, which is highly regulated by removing cytosolic long-lived proteins and damaged organelles from cells. Inappropriate stimulation of autophagy may promote cell death, whereas other researches point to offer protective effects for autophagy (2-4). The sepsis-induced myocardial injury is also modeled by lipopolysaccharide (LPS)-induced inflammation and oxidative stress (5). LPS-induced autophagy is a cytoprotective response to suppress programmed cell death (6). However, excessive autophagy can also induce cardiac dysfunction and cell death (7). Recently, it has been found that LPS leads to multiorgan dysfunction and is critical in myocardial dysfunction. LPS is reported to induce mitochondrial biogenesis and autophagy in cardiomyocytes (6). Researches indicate that LPS-induced cardiomyocyte autophagy is a leading cause of death in patients with sepsis. The natural medicinal plants have been investigated as a potential therapeutic strategy for dysfunction of cardiovascular disease via regulating autophagy (8, 9). Thus, the moderation of autophagy is essential to reduce LPS-induced myocardial injury.

Eupafolin is an active component of *Eupatorium*

perfoliatum L., which is a traditional herbal medicine from China and India (10, 11). Eupafolin has been investigated to show anti-inflammatory, anti-oxidant and anti-tumor effects (12-14). Various flavonoids with anti-oxidant effects have been revealed to suppress lipid peroxidation and increase the anti-oxidation capacity of myocardial cells (15, 16). Eupafolin is also a flavonoid compound. Recent studies reveal various effects of eupafolin on pathologies including, but not limited, inflammation in acute renal injury, apoptosis in cervical cancer and mitochondrial metabolism (12, 17, 18). However, its pharmacological effects on cardiac disease have been poorly studied. Although previous studies have evaluated some effects of eupafolin, its specific effects on cardiomyocyte autophagy are unclear.

Eupafolin has been reported to exert anti-inflammation and anti-oxidative stress properties by regulating various signaling pathways, including Jun N-terminal kinase (JNK), nuclear factor- κ B (NF- κ B), mitogen-activated protein kinases (MAPK), and protein kinase B (AKT) pathways (19-21). In addition, cyclooxygenase-2 (COX-2) usually acts in inflammatory response, which has been revealed to be affected by eupafolin (22). Previous research indicated that LPS-induced autophagy is associated with phosphatidylinositol-3-kinase/ AKT/ mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway (23, 24). PI3K/AKT/

*Corresponding author: Yan Gao. Function Testing Lab, Shaanxi Provincial People's Hospital, No. 256 Youyi west road, beilin district, Xi'an, 710068, Shaanxi P.R. China. Tel: +86-029-85251331-2343; Email: caoruiyun_bd@126.com

mTOR signaling pathway has been a classical pathway in regulating autophagy. The kinase mTOR includes two mTOR complexes, mTORC1 and mTORC2. mTORC1 is a negative regulator of autophagy (25). In addition, PI3K/AKT pathway is an upstream modulator of mTORC1 (26, 27). A research has shown that LPS-induced autophagy is regulated by AKT/mTOR pathway (28). Beclin-1 is a core component of Class III PI3K complex, which is associated with a variety of cellular processes such as autophagy (29). Researches indicated that mTOR can negatively regulate Beclin-1 expression in many kinds of diseases such as cerebral ischemia reperfusion and hepatocellular carcinoma (30, 31). p62, a classical cargo receptor of autophagy, is an LC3-interacting protein and is constantly degraded by the autophagy-lysosome system (32).

Limited studies involve the effects of eupafolin on LPS-induced myocardial injury, so we hypothesized that eupafolin could attenuate LPS-induced autophagy through downregulating PI3K/AKT/mTOR signaling pathway. This study provides a theoretical basis for the role of eupafolin in the treatment of myocardial injury.

Materials and Methods

Cell culture and treatment

Human myocardial cell lines HL-1 was cultured in Claycomb medium (sigma), supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco), 2 mM L-glutamine (Gibco) and 100 µM noradrenalin (Gibco), and incubated at 37 °C, and 5% CO₂. Treatment with rapamycin (0.1 µM), and eupafolin (10, 20, 50 µM) were accomplished by adding these compounds 1 hr before LPS treatment. To establish cardiomyocyte autophagy, cells were treated with LPS (sigma) in concentration of 100 µg/ml or 200 µg/ml for 0, 4, 6, 8, and 16 hr.

CCK-8

Cell viability was examined by Cell Count Kit-8 (CCK-8) assay. Cells were seeded at 1.5×10^3 cells per well in 96-well culture plates overnight and treated with LPS 100 µg/ml or 200 µg/ml for 0, 4, 6, 8, and 16 hr at 37 °C in a 5% CO₂ atmosphere. Subsequently, CCK-8 (Transgen Biotech, Shanghai, China) solution (10% of the medium) was added into each well and incubated for 4 hr. The absorbance was measured at 490 nm.

Immunofluorescence

Green fluorescent protein-microtubule associated protein light chain 3 (GFP-LC3) was transfected into cells using Effectene transfection reagents (Qiagen) according to the user's instructions. The transfection efficiency was visualized by fluorescence microscopy. GFP-LC3-transfected cells were subsequently incubated with LPS or eupafolin in culture medium for the indicated times. Cells were fixed with 4% paraformaldehyde at room temperature for 10 min. Then, cells were inspected at $\times 100$ magnification.

Western blot

Cells were seeded at concentration of 8×10^5 cells in each 6-cm dish overnight. Cells were then treated with LPS or eupafolin for indicated times. The cells were harvested and extracted by radioimmunoprecipitation

assay (RIPA) buffer (Sigma) at 4 °C. After 15 min centrifugation at 15000 g, supernatants were collected and stored at -20 °C. Total proteins (40 µg) were resolved by SDS-PAGE, and transferred onto a polyvinylidene difluoride membranes (PVDF) and incubated with the following antibodies: glyceraldehyde-3-phosphate dehydrogenase GAPDH (1/1000; Cell signaling technology), Beclin-1, p62 (1/1000; Cell signaling technology), phosphor-PI3K (1/1000; Cell signaling technology), PI3K (1/1000; Cell signaling technology), phosphor-AKT (1/1000; Cell signaling technology), AKT (1/1000; Cell signaling technology), phosphor-mTOR (1/1000; Cell signaling technology), mTOR (1/1000; Cell signaling technology). Blots were following incubated with horseradish peroxidase (HRP)-linked goat anti-rabbit IgG antibody for 1 hr at room temperature. The bands were detected using the ECL chemiluminescent substrate reagent kit (Thermo Fisher Scientific). The intensity of each band was finally analyzed using a densitometer.

Statistical analysis

Results were analyzed with Graphpad 6.0. The probability of statistically significant differences was tested by GraphPad Prism 6.0 using one-way ANOVA followed by Turkey's *post hoc* test for multiple comparisons and students' t test for comparison between groups. Values were expressed as means \pm SD of at least three independent experiments. *P*-value of less than 0.05 was considered statistically significant.

Results

LPS induced autophagy of cardiomyocyte

To choose the best condition that can induce autophagy of cardiomyocyte, cell viability was first detected. Cell viability was decreased to 50% at condition of LPS 100 µg/ml for 16 hr and LPS 200 µg/ml for 8 hr (Figure 1). Subsequently, protein 2 light chain 3 (LC3II) was significantly increased at 100 µg/ml or 200 µg/ml for 8 hr (Figure 2). The autophagic proteins Beclin-1 and p62 were detected by western blot. Beclin-1 was significantly increased and p62 was decreased significantly at 16 hr both in cells treated with LPS 100 µg/ml or 200 µg/ml (Figure 3). In order to establish a cardiomyocyte autophagy, we chose the condition of LPS 200 µg/ml induced for 8 hr to finish




Figure 1. Effects of eupafolin on cell viability. CCK-8 assay was used to detect cell viability of cardiomyocyte after treatment with eupafolin (100 µg/ml or 200 µg/ml). Data were presented with mean \pm SD, **P*<0.05, ***P*<0.01, versus 100 µg/ml




Figure 2. LPS-induced autophagy in cardiomyocyte. A: LPS with 100 µg/ml induced expression of LC3II at 0 hr, 4 hr, 6 hr, 8 hr and 16 hr. B: LPS with 200 µg/ml induced expression of LC3II at 0 hr, 4 hr, 6 hr, 8 hr and 16 hr. Data were expressed as mean±SD, * P <0.05, ** P <0.01, *** P <0.001 versus 0 hr. LPS: Lipopolysaccharide, LC3II: Protein 2 light chain 3

the further study.

Eupafolin reversed cell autophagy in cardiomyocyte

According to previous investigation (12, 33), three concentration of eupafolin was used to evaluate the effects of eupafolin on LPS-induced autophagy and cell viability. Results showed that eupafolin prevented myocardial injury induced by LPS (Figure 4A). LC3II

expression in LPS-induced cardiomyocyte was significantly decreased after treating with eupafolin 50 µM (Figure 4B). Beclin-1 was significantly decreased and p62 was significantly increased after treating with eupafolin 50 µM (Figure 4C). Thus, eupafolin improves LPS-induced autophagy and cell viability in




Figure 3. LPS-induced expression of Beclin-1 and p62 in cardiomyocyte. A: LPS with 100 µg/ml induced expression changes of Beclin-1 and p62 at 0 hr, 4 hr, 6 hr, 8 hr and 16 hr. B: LPS with 200 µg/ml induced expression of Beclin-1 and p62 at 0 hr, 4 hr, 6 hr, 8 hr and 16 hr. Data were expressed as mean±SD, * P <0.05, ** P <0.01, *** P <0.001 versus 0 hr. LPS: Lipopolysaccharide




Figure 4. Eupafolin improves LPS-induced autophagy and viability in cardiomyocyte. A: Cell viability of cardiomyocyte was detected after treatment with LPS and eupafolin. B: eupafolin alleviated expression of LC3II in LPS-induced cardiomyocyte. C: Effects of eupafolin on expression of Beclin-1 and p62 in LPS-induced cardiomyocyte. Data were presented with mean±SD. * $P<0.05$, ** $P<0.01$, *** $P<0.001$, versus eupafolin 0 μM. LPS: Lipopolysaccharide, LC3II: Protein 2 light chain 3

cardiomyocyte.

Eupafolin promoted PI3K/AKT/mTOR signaling pathway

We further investigated the effects of eupafolin on PI3K/AKT/mTOR signaling pathway. As shown in Figure 5, eupafolin significantly upregulated the expression levels of p-PI3K, p-AKT and p-mTOR in LPS-induced cardiomyocyte. To further investigate whether eupafolin inhibited autophagy in cardiomyocyte via

PI3K/AKT/mTOR signaling pathway, rapamycin, an inhibitor of mTOR, was used before eupafolin treatment. Results showed that rapamycin significantly increased LC3II expression even though cardiomyocytes treated with LPS and eupafolin at the same time (Figure 6A). In addition, the expression alterations of Beclin-1 and p62 also proved that rapamycin can reverse the anti-autophagy effect of eupafolin (Figure 6B). These results indicated that eupafolin exerted negative effect on LPS-




Figure 5. PI3K/AKT/mTOR was activated via eupafolin in LPS-induced cardiomyocyte. Data were presented with mean±SD. ** $P<0.01$, *** $P<0.001$, versus eupafolin untreated cells. LPS: Lipopolysaccharide; PI3K/AKT/mTOR: Phosphatidylinositol-3-kinase/ protein kinase B/ mammalian target of rapamycin




Figure 6. Eupafolin exerts effects on autophagy and viability via PI3K/AKT/mTOR signaling pathway. A: mTOR inhibitor (rapamycin) reversed the effects of eupafolin on expression of LC3II in LPS-induced cardiomyocyte. B: Effects of eupafolin on expression of Beclin-1 and p62 in LPS-induced cardiomyocyte were reversed by mTOR inhibitor. Data were presented with mean±SD. *** $P < 0.001$ versus mTOR untreated group. LPS: Lipopolysaccharide; LC3II: Protein 2 light chain 3; PI3K/AKT/mTOR: Phosphatidylinositol-3-kinase/ protein kinase B/ mammalian target of rapamycin

induced cardiomyocyte autophagy.

Discussion

In the present study, we demonstrated that LPS-induced autophagy is associated with excessive autophagy. Eupafolin attenuated the LPS-induced autophagy by activation of PI3K/AKT/mTOR signaling pathway. As per our knowledge, this is the first study to investigate the effects of eupafolin on autophagy in cardiomyocytes exposed to LPS.

Because myocardial injury caused by sepsis is very similar to LPS-induced myocardial injury (5, 34), LPS is often used for myocardial injury modeling. Autophagy exerts cardioprotection by removing toxic oxidative protein (35). However, excessive autophagy would result in autophagic cell death (36). The decrease of age-related autophagy may lead to heart diseases, including LPS-induced myocardial injury (37). In the present *in vitro* study, eupafolin could decrease the LPS-induced autophagy and increase the cardiomyocyte viability. Thus, eupafolin plays a potential role in protecting myocardium by inhibiting myocardial autophagy.

Autophagy is a conserved process, which involves the degradation and cytosolic components reusing (38). Autophagic initiation is usually controlled by Beclin-1 and LC-3II, which their levels are correlated with the extent of autophagosomes formation. Additionally, p62 is involved in maturation of autophagosomes by selectively

incorporating into autophagosomes and subsequently degradation of autolysosomes (38). In this investigation, results showed that LPS exposure promotes autophagic flux by Beclin-1 and LC3II upregulation and p62 degradation. Eupafolin is an important herbal product that exerts anti-inflammatory effects in LPS-induced inflammation (33). Tissue injury promotes a local and systemic inflammatory response without microbial pathogen, a process which induces further injury and a mechanism of disease progression (39). Autophagy may play a permissive role in inflammation observed in the heart during cardiac remodeling (40). In this study, eupafolin inhibited the LPS-induced autophagy by regulating the expression of Beclin-1 and LC3II, thereby reducing the expression of p62.

A significant body of evidence reveals that PI3K/AKT pathway serves as a critical signaling pathway in cell survival; however, some intriguing reports suggest that this pathway could also promote cell death, especially for necrotic cell death (41). The promotion of eupafolin on PI3K/AKT pathway corresponds to the activation of AKT downstream targets. mTOR is a major downstream target of AKT, and activation of PI3K/AKT/mTOR has been revealed to inhibit autophagy and apoptosis (42). Autophagy involves in complex signaling pathway including the protein kinases mTOR and PI3K (43). In this study, eupafolin activated PI3K/AKT/mTOR signaling pathway and rapamycin, an inhibitor of mTOR,

was used to confirm that eupafolin reduced autophagy via inhibiting PI3K/AKT/mTOR signaling pathway.

Conclusion

LPS, a Gram-negative bacterial endotoxin, is widely used to induce sepsis via driving aberrant myocardial injury. Our investigation indicated that eupafolin can inhibit LPS-induced autophagic flux in cardiomyocyte *in vitro*, and eupafolin promotes myocardial viability. In addition, the effect of eupafolin on autophagy was mediated by PI3K/AKT/mTOR signaling pathway in cardiomyocyte. However, *in vivo* studies are still required to further prove the protective effects of eupafolin on myocardium. Furthermore, the effects of eupafolin on LPS induced oxidative injury and inflammation, which are associated with autophagy, and also required further investigation.

Acknowledgment

Not applicable.

Conflicts of Interest

All contributing authors declare no conflicts of interest.

References

- Gustafsson AB, Gottlieb RA. Eat your heart out: Role of autophagy in myocardial ischemia/reperfusion. *Autophagy*. 2008;4:416-421.
- Menk M, Graw JA, Poyraz D, Mobius N, Spies CD, von Haefen C. Chronic Alcohol Consumption Inhibits Autophagy and Promotes Apoptosis in the Liver. *Int J Med Sci*. 2018;15:682-688.
- Hamacher-Brady A, Brady NR, Gottlieb RA, Gustafsson AB. Autophagy as a protective response to Bnip3-mediated apoptotic signaling in the heart. *Autophagy*. 2006;2:307-309.
- Gu Y, Gao L, Chen Y, Xu Z, Yu K, Zhang D, et al. Sanggenon C protects against cardiomyocyte hypoxia injury by increasing autophagy. *Mol Med Rep*. 2017;16:8130-8136.
- Zhang N, Feng H, Liao HH, Chen S, Yang Z, Deng W, et al. Myricetin attenuated LPS induced cardiac injury *in vivo* and *in vitro*. *Phytother Res*. 2018;32:459-470.
- Hickson-Bick DL, Jones C, Buja LM. Stimulation of mitochondrial biogenesis and autophagy by lipopolysaccharide in the neonatal rat cardiomyocyte protects against programmed cell death. *J Mol Cell Cardiol*. 2008;44:411-418.
- Wang S, Ren J. Role of autophagy and regulatory mechanisms in alcoholic cardiomyopathy. *Biochim Biophys Acta Mol Basis Dis*. 2018;1864(6 Pt A):2003-2009.
- Hashemzaei M, Entezari Heravi R, Rezaee R, Roohbakhsh A, Karimi G. Regulation of autophagy by some natural products as a potential therapeutic strategy for cardiovascular disorders. *Eur J Pharmacol*. 2017;802:44-51.
- Sameiyan E, Hayes AW, Karimi G. The effect of medicinal plants on multiple drug resistance through autophagy: A review of *in vitro* studies. *Eur J Pharmacol*. 2019;852:244-253.
- Hensel A, Maas M, Sendker J, Lechtenberg M, Peterleit F, Deters A, et al. *Eupatorium perfoliatum* L.: phytochemistry, traditional use and current applications. *J Ethnopharmacol*. 2011;138:641-451.
- Miura K, Kikuzaki H, Nakatani N. Antioxidant activity of chemical components from sage (*Salvia officinalis* L.) and thyme (*Thymus vulgaris* L.) measured by the oil stability index method. *J Agric Food Chem*. 2002;50:1845-1851.
- Zhang H, Chen MK, Li K, Hu C, Lu MH, Situ J. Eupafolin nanoparticle improves acute renal injury induced by LPS through inhibiting ROS and inflammation. *Biomed Pharmacother*. 2017;85:704-711.
- Maas M, Deters AM, Hensel A. Anti-inflammatory activity of *Eupatorium perfoliatum* L. extracts, eupafolin, and dimeric guaianolide via iNOS inhibitory activity and modulation of inflammation-related cytokines and chemokines. *J Ethnopharmacol*. 2011;137:371-381.
- Liu K, Park C, Chen H, Hwang J, Thimmegowda NR, Bae EY, et al. Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling. *Mol Carcinog*. 2015;54:751-760.
- Yang WJ, Liu C, Gu ZY, Zhang XY, Cheng B, Mao Y, et al. Protective effects of acacetin isolated from *Ziziphora clinopodioides* Lam. (Xintahua) on neonatal rat cardiomyocytes. *Chin Med*. 2014;9:28-33.
- Zhou Z, Li N, Zhang HF, Wang QQ, Yu Q, Wang F, et al. Simultaneous quantitative analysis of 11 flavonoid derivatives with a single marker in persimmon leaf extraction and evaluation of their myocardium protection activity. *J Nat Med*. 2019;73:404-418.
- Chung KS, Choi JH, Back NI, Choi MS, Kang EK, Chung HG, et al. Eupafolin, a flavonoid isolated from *Artemisia princeps*, induced apoptosis in human cervical adenocarcinoma HeLa cells. *Mol Nutr Food Res*. 2010;54:1318-1328.
- Herrerias T, de Oliveira BH, Gomes MA, de Oliveira MB, Carnieri EG, Cadena SM, et al. Eupafolin: Effect on mitochondrial energetic metabolism. *Bioorg Med Chem*. 2008;16:854-861.
- Tsai MH, Lin ZC, Liang CJ, Yen FL, Chiang YC, Lee CW. Eupafolin inhibits PGE2 production and COX2 expression in LPS-stimulated human dermal fibroblasts by blocking JNK/AP-1 and Nox2/p47(phox) pathway. *Toxicol Appl Pharmacol*. 2014;279:240-251.
- Chen X, Han R, Hao P, Wang L, Liu M, Jin M, et al. Nepetin inhibits IL-1beta induced inflammation via NF-kappaB and MAPKs signaling pathways in ARPE-19 cells. *Biomed Pharmacother*. 2018;101:87-93.
- Ko HH, Chiang YC, Tsai MH, Liang CJ, Hsu LF, Li SY, et al. Eupafolin, a skin whitening flavonoid isolated from *Phylla nodiflora*, downregulated melanogenesis: Role of MAPK and Akt pathways. *J Ethnopharmacol*. 2014;151:386-393.
- Lee CW, Lin ZC, Hsu LF, Fang JY, Chiang YC, Tsai MH, et al. Eupafolin ameliorates COX-2 expression and PGE2 production in particulate pollutants-exposed human keratinocytes through ROS/MAPKs pathways. *J Ethnopharmacol*. 2016;189:300-309.
- Liu J, Wang X, Zheng M, Luan Q. Lipopolysaccharide from *Porphyromonas gingivalis* promotes autophagy of human gingival fibroblasts through the PI3K/Akt/mTOR signaling pathway. *Life Sci*. 2018;211:133-139.
- Xu X, Li H, Gong Y, Zheng H, Zhao D. Hydrogen sulfide ameliorated lipopolysaccharide-induced acute lung injury by inhibiting autophagy through PI3K/Akt/mTOR pathway in mice. *Biochem Biophys Res Commun*. 2018;507:514-518.
- Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. *J Biol Chem*. 1998;273:3963-3966.
- Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007;129:1261-1274.
- Hay N. The Akt-mTOR tango and its relevance to cancer. *Cancer Cell*. 2005;8:179-183.
- Han F, Xiao QQ, Peng S, Che XY, Jiang LS, Shao Q, et al. Atorvastatin ameliorates LPS-induced inflammatory response by autophagy via AKT/mTOR signaling pathway. *J Cell Biochem*. 2018;119:1604-1615.
- Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. *Trends Cell Biol*. 2010;20:355-362.
- Yang T, Li D, Liu F, Qi L, Yan G, Wang M. Regulation on

- Beclin-1 expression by mTOR in CoCl₂-induced HT22 cell ischemia-reperfusion injury. *Brain Res.* 2015;1614:60-66.
31. Zou M, Lu N, Hu C, Liu W, Sun Y, Wang X, *et al.* Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling. *Cell Signal.* 2012;24:1722-1732.
32. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, *et al.* p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol* 2005;171:603-614.
33. Chen CC, Lin MW, Liang CJ, Wang SH. The anti-inflammatory effects and mechanisms of eupafolin in lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. *PLoS One* 2016;11:e0158662.
34. Wang F, Jin Z, Shen K, Weng T, Chen Z, Feng J, *et al.* Butyrate pretreatment attenuates heart depression in a mice model of endotoxin-induced sepsis via anti-inflammation and anti-oxidation. *Am J Emerg Med* 2017;35:402-409.
35. Gottlieb RA, Finley KD, Mentzer RM, Jr. Cardioprotection requires taking out the trash. *Basic Res Cardiol* 2009;104:169-180.
36. Chang L, Chai X, Chen P, Cao J, Xie H, Zhu J. miR-181b-5p suppresses starvation-induced cardiomyocyte autophagy by targeting Hspa5. *Int J Mol Med* 2019;43:143-154.
37. Li F, Lang F, Zhang H, Xu L, Wang Y, Hao E. Role of TFEB mediated autophagy, oxidative stress, inflammation, and cell death in endotoxin induced myocardial toxicity of young and aged mice. *Oxid Med Cell Longev* 2016;2016:5380319.
38. Esteban-Martinez L, Boya P. Autophagic flux determination *in vivo* and *ex vivo*. *Methods.* 2015;75:79-86.
39. Abbate A. The heart on fire: inflammasome and cardiomyopathy. *Exp Physiol* 2013;98:385.
40. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, *et al.* Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. *Nature* 2012;485:251-255.
41. Zhang L, Wang H, Cong Z, Xu J, Zhu J, Ji X, *et al.* Wogonoside induces autophagy-related apoptosis in human glioblastoma cells. *Oncol Rep* 2014;32:1179-1187.
42. Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, *et al.* Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. *Carcinogenesis.* 2013;34:1331-1342.
43. Meijer AJ, Codogno P. Signalling and autophagy regulation in health, aging and disease. *Mol Aspects Med.* 2006;27:411-425.